Navigation Links
Small-Cell Lung Cancer Drug Market Will More Than Double to Over $684 Million in 2017
Date:4/8/2009

Although Market Growth Will be Robust, Drug Development Has Been Disappointing in Recent Years, According to a New Report from Decision Resources

WALTHAM, Mass., April 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the small-cell lung cancer drug market will more than double from just under $250 million in 2007 to more than $684 million in 2017, owing to the launches of Genentech/Roche/Chugai's Avastin and Celgene's amrubicin (currently marketed in Japan as Calsed by Nippon Kayaku) to treat the indication.

The new Pharmacor report entitled Small-Cell Lung Cancer finds that the launches, beginning in 2012, of Avastin as a first-line add-on to standard chemotherapy and amrubicin as a second-line therapy will drive robust 22 percent annual growth from 2012 to 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

Although market growth will be robust from 2012 to 2017, drug development in recent years in small-cell lung cancer has, overall, been very disappointing. Recent clinical trials have largely eliminated Pfizer's Camptosar/Campto (Daiichi Sankyo's Topotecin), Eli Lilly's Alimta, and GlaxoSmithKline/Nippon Kayaku's Hycamtin from potential first-line status in the indication. Furthermore, despite the impressive sales that Avastin and amrubicin will add to the market, these therapies will have only niche roles in small-cell lung cancer treatment.

"Avastin and amrubicin will each garner only a limited share of the total small-cell lung cancer patient population," said Decision Resources Analyst Janie Mackay, Ph.D. "However, their high price points in an increasingly generic market, mean that those patient shares will translate into substantial market shares."

Despite the disappointing drug development environment, the recent designation of small-cell lung cancer as an orphan disease -- owing to reduced growth rates of the indication -- may help drive future drug development. In the United States, a drug approved to treat an orphan disease receives seven years' market exclusivity and in Europe orphan drugs generally receive 10 years' marketing exclusivity.

"If a drug developer were to produce a novel efficacious agent for small-cell lung cancer, they would benefit from the financial advantages that orphan-drug designation offers in the world's major pharmaceutical markets," Dr. Mackay said.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

          All company, brand, or product names contained in this
        document may be trademarks or registered trademarks of their
                       respective holders.



    For more information, contact:

    Decision Resources            Decision Resources, Inc.
    Christopher Comfort           Elizabeth Marshall
    781-296-2597                  781-296-2563
    ccomfort@dresources.com       emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... 19, 2017 , ... Bone Solutions Inc. (BSI), an orthobiologics ... medical device, OsteoCrete®. OsteoCrete® bone void filler is designed to assist with bone ... a critical property for bone health and development. , “We’re excited to bring ...
(Date:9/19/2017)... ... September 19, 2017 , ... Premiere Long Island dental office Gold ... named one of the best dentists in America under age 40 by Incisal Edge ... Every fall, the magazine features the best 40 dentists under the age of 40 ...
(Date:9/19/2017)... ... 19, 2017 , ... Inc. magazine ranked Endo-Systems ... the nation's fastest-growing private companies. The list represents a unique look at the ... and midsized businesses. Endo-Systems is a leading B2B distributor of today’s most scientifically ...
(Date:9/18/2017)... , ... September 18, 2017 , ... TransLuma is a set of dissolving transitions created ... dissolve in or dissolve away the luminance of a scene without the use of keyframes. ... next scene before fully transitioning over. , TransLuma allows editors to gradually dissolve away the ...
(Date:9/18/2017)... CA (PRWEB) , ... September 18, 2017 , ... Cosmetic ... on its website. According to the senior editor of Cosmetic Tow, “Our forum section ... as well as provide answers to other forum members thinking about having cosmetic surgery. ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... , Sept. 12, 2017  Consumer reviews on the independent ... as the number one company for hearing aids, ranking it ... fifteen other brands. ... Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides high performance, ...
(Date:9/9/2017)... WASHINGTON , Sept. 8, 2017 ... Mobile MRI Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, ... to Washington, D.C. offering free MRI brain scans to the public.Where:  ... – will be parked at 501 K Street NW, Washington, D.C.What:BTF brings ...
(Date:9/9/2017)... 2017  Eli Lilly and Company (NYSE: ... data for lasmiditan, an investigational, oral, first-in-class molecule for ... improvements compared to placebo in the Phase 3 SPARTAN ... 18th Congress of the International Headache Society (IHC) in ... presented today demonstrate lasmiditan,s potential to reduce pain and ...
Breaking Medicine Technology: